中国实用外科杂志Issue(1)：27-29,3.DOI:10.7504/CJPS.ISSN1005-2208.2015.01.08
2014年ASCO乳腺癌临床实践指南解读--HER2阴性（或未知）晚期乳腺癌化学和靶向治疗
Interpretation of the ASCO practice guideline:Chemotherapy and targeted for women with HER2-Negative (or unknown) advanced breast cancer
摘要
Abstract
In October 2014 Journal of Clinical Oncology,it published the Chemotherapy and Targeted for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer:ASCO Practice Guideline. Recommendations include:Endocrine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor-positive metastatic breast cancer unless improvement is medically necessary (eg, immediately life-threatening disease).Single agent is preferable to combination chemotherapy,and longer planned duration improves outcome but must be balanced against toxicity.There is no single optimal first-line or subsequent line chemotherapy,and choice of treatment will be determined by multiple factors including prior therapy,toxicity,performance status,comorbid conditions,and patient preference.The role of bevacizumab remains controversial.Other targeted therapies have not so far been shown to enhance chemotherapy outcome in HER2-negative breast cancer.关键词
晚期乳腺癌/HER2阴性Key words
advanced breast cancer/HER2-negative分类
医药卫生引用本文复制引用
高国璇,刘荫华..2014年ASCO乳腺癌临床实践指南解读--HER2阴性（或未知）晚期乳腺癌化学和靶向治疗[J].中国实用外科杂志,2015,(1):27-29,3.基金项目
首都特色应用研究项目 （）
